Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode

https://doi.org/10.1016/j.bmcl.2010.01.078Get rights and content

Abstract

The work described herein demonstrates the utility of structure-based drug design (SBDD) in shifting the binding mode of an HTS hit from a DFG-in to a DFG-out binding mode resulting in a class of novel potent CSF-1R kinase inhibitors suitable for lead development.

Section snippets

Acknowledgments

The authors thank Daniel Walker and Michael Ennis for critical review of this manuscript, and the Advanced Photon Source and the staff at beamline 21ID-D for their help in the collection of diffraction data.

References and notes (11)

  • F.J. Pixley et al.

    Trends Cell Biol.

    (2004)
  • R.J. Patch et al.

    Bioorg. Med. Chem. Lett.

    (2007)
    C.R. Illig et al.

    Bioorg. Med. Chem. Lett.

    (2008)
    S.K. Meegalla et al.

    Bioorg. Med. Chem. Lett.

    (2008)
    H. Huang et al.

    J. Med. Chem.

    (2009)
    Y. Uemura et al.

    J. Neuroimmunol.

    (2008)
    H. Ohno et al.

    Eur. J. Immunol.

    (2008)
    J.G. Conway et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (2005)
    J.G. Conway et al.

    J. Pharmacol. Exp. Ther.

    (2008)
    C.L. Manthey et al.

    Ann. Rep. Med. Chem.

    (2009)
    C.L. Manthey et al.

    Mol. Cancer Ther.

    (2009)
  • C. Pargellis et al.

    Nat. Struct. Biol.

    (2002)
    Z.A. Knight et al.

    Chem. Biol.

    (2005)
    D.C. Swinney

    Nat. Rev. Drug Disc.

    (2004)
    D.C. Swinney

    Curr. Top. Med. Chem.

    (2006)
There are more references available in the full text version of this article.

Cited by (31)

  • CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment

    2023, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Beyond an off-positioned DFG motif, the existence of multiple non-bond interactions break the conserved salt bridge between Lys616 and Glu633, which further interrupt the catalytic activity of CSF1R. To the best of our knowledge, only one co-crystallography demonstrates CSF1R under ‘DFG-in’ conformation (PDB ID: 3LCD) [151]. Under this status, the inhibitor occupies a small volume of the binding pocket, which is deemed detrimental in gaining premium binding affinity and kinase selectivity to inhibitors under ‘DFG-out’ status.

  • Discovery of a CSF-1R inhibitor and PET tracer for imaging of microglia and macrophages in the brain

    2022, Nuclear Medicine and Biology
    Citation Excerpt :

    Furthermore, substitution of methyl groups with fluoroethyl functionalities towards labeling the compound with fluorine-18, a clinically more relevant isotope, was envisioned. The synthesis of the target compound and the fluoroethyl analogues (Schemes 1 and 2) were largely based on reported literature procedures [21]. Hybrid molecule 4 was synthesized starting with nucleophilic substitution reaction between 5-bromo-2-chloro-3-methoxypyridine and (4-methoxyphenyl)methanol.

  • Fenugreek steroidal saponins hinder osteoclastogenic bone resorption by targeting CSF-1R which diminishes the RANKL/OPG ratio

    2021, International Journal of Biological Macromolecules
    Citation Excerpt :

    Such conformational change contributes to the kinase activity. Additionally, in the “DFG-out” state, the positions of ASP796 and PHE797 shift, as the ASP796 points away from the ATP binding site, thus hinders the coordination of Mg+2 ion inhibiting the kinase activity of the CSF-1R (Fig. 6b) [39,61]. To further evaluate the conformational changes from DFG-in to DFG-out state after binding of inhibitor, we performed MD simulation of CSF-1R (PDB ID: 2I1M) and monitored its conformational changes from 10 ns to 100 ns.

View all citing articles on Scopus
View full text